to be performed by vaccine manufacturers, in addition to their routine regulatory obligations, when the pandemic vaccines are used have been defined by the Committee on Human Medicinal Products (CHMP). These activities include conducting a prospective safety cohort study for each vaccine, surveillance of adverse events of special interest (AESI), monitoring of special population groups such as pregnant women, children and immunocompromised subjects, and conducting studies on effectiveness and immunogenicity.